Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949448 | 0.96 | SLC6A4 (0.54) | SLC6A4CYP1A2CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL27500639 | 0.94 | SLC6A4 (0.52) | SLC6A4CYP1A2CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL649226 | 0.91 | HTR2A (0.53) | SLC6A4CYP1A2CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL9208031 | 0.83 | CYP19A1 (0.56) | SLC6A4CYP1A2CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL1177062 | 0.82 | MEN1 (0.53) | SLC6A4CYP1A2CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL320187 | 0.82 | NR3C1 (0.52) | SLC6A4CYP1A2CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL5637174 | 0.81 | HTR2A (0.55) | SLC6A4HTR1AHTR2AMPO | |
| SCHEMBL3702253 | 0.81 | MPO (0.62) | SLC6A4HTR2AMPO | |
| SCHEMBL8243669 | 0.80 | SLC6A4 (0.62) | SLC6A4CYP1A2CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL4362228 | 0.78 | SLC6A4 (0.61) | SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709323-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| CN-107709323-A | Oxipurinol class compound and its application | 广东众生药业股份有限公司 | 2018-02-16 | — | — | CN | disclosed |
| WO-2016184312-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | 南京明德新药研发股份有限公司 | 2016-11-24 | — | — | WO | disclosed |
| CN-101016296-A | Muscarinic agonists | ACADIA PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0644187-B1 | Antimigraine cyclobutenedione derivatives of tryptamines | BRISTOL MYERS SQUIBB CO (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0292840-B1 | Cyclic amine derivatives, medicaments containing these compounds and procedure for their preparation | THOMAE GMBH DR K (DE) | 1995-08-09 | — | — | EP | disclosed |
| EP-0644187-A1 | Antimigraine cyclobutenedione derivatives of tryptamines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-22 | — | — | EP | disclosed |
| US-5382592-A | Antimigraine cyclobutenedione derivatives of tryptamines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| US-5175157-A | Cardiovascular disorders | BOEHRINGER INGELHEIM GMBH (DE) | 1992-12-29 | — | — | US | disclosed |
| US-5116986-A | HETEROAROMATIC AMINE DERIVATIVES | DR. KARL THOMAE GMBH (DE) | 1992-05-26 | — | — | US | disclosed |
| US-4912115-A | Cardiovascular disorders | DR. KARL THOMAE GMBH (DE) | 1990-03-27 | — | — | US | disclosed |
| EP-0292840-A2 | Cyclic amine derivatives, medicaments containing these compounds and procedure for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-11-30 | — | — | EP | disclosed |
| EP-0269968-A2 | Heteroaromatic amine derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | SLC6A4 1094/4885CYP1A2 98/4885CYP3A4 500/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | SLC6A4 1094/4885CYP1A2 98/4885CYP3A4 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.